Skip to main content
. 2024 Sep 1;15(6):389–395. doi: 10.6004/jadpro.2024.15.6.4

Figure 2.

Figure 2

CADENZA trial results. Visual abstract demonstrating results from the CADENZA trial. The CADENZA trial was a 26-week randomized, placebo-controlled phase III study to assess safety and efficacy of sutimlimab in patients with CAD without recent (within 6 months prior to enrollment) transfusion history. Reproduced from Röth et al. (2022).